|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_programs
|
Dr. Michael J. H. Smith
|
|
gptkbp:acquisition
|
Medi Gene AG (2018)
Astellas Pharma (2018)
|
|
gptkbp:clinical_trial
|
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma
solid tumors
|
|
gptkbp:conducts_research_on
|
Dr. Roger Dansey
|
|
gptkbp:employees
|
approximately 1,000
|
|
gptkbp:focus
|
cancer therapeutics
|
|
gptkbp:founded
|
gptkb:1998
|
|
gptkbp:founder
|
Clayton A. Wright
|
|
gptkbp:head_of_clinical_development
|
Dr. John O. Armitage
|
|
gptkbp:head_of_manufacturing
|
Dr. Sarah J. H. Brown
|
|
gptkbp:head_of_regulatory_affairs
|
Dr. Jennifer A. L. H. Lee
|
|
gptkbp:headquarters
|
gptkb:Bothell,_Washington
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Seattle Genetics
|
|
gptkbp:key_people
|
gptkb:Thomas_C._Reynolds
Clayton A. Wright
|
|
gptkbp:market_cap
|
$20 billion (2021)
|
|
gptkbp:notable_awards
|
Best Places to Work (2020)
Best Workplaces for Diversity (2020)
Top 100 Best Companies to Work For (2021)
Innovative Company Award (2019)
Top 50 Biotech Companies (2021)
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Astellas_Pharma
|
|
gptkbp:products
|
gptkb:Tukysa
gptkb:Adcetris
|
|
gptkbp:research_focus
|
biomarkers
targeted therapies
immuno-oncology
precision medicine
antibody-drug conjugates
|
|
gptkbp:revenue
|
$1.1 billion (2020)
|
|
gptkbp:stock_symbol
|
gptkb:SGEN
|
|
gptkbp:subsidiaries
|
Seattle Genetics Asia
Seattle Genetics Australia
Seattle Genetics Canada
Seattle Genetics Europe
Seattle Genetics Japan
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.seattlegenetics.com
|
|
gptkbp:bfsParent
|
gptkb:Brentuximab_vedotin
|
|
gptkbp:bfsLayer
|
6
|